Bayer and MOMA Therapeutics enter collaboration and license agreement in oncology
8 October 2024-Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, announced that they have entered into a collaboration, under an option and exclusive license agreement, to develop and commercialize a small molecule oncology program based on MOMA’s proprietary Knomatic platform
Under the agreement, Bayer will be responsible for completing further preclinical, development and commercial activities. Under the agreement, Bayer will gain access to the program itself along with results generated via MOMA’s Knomatic platform. This platform integrates deep structural insights with advanced hit-finding technologies and computation-enabled lead optimization to accelerate the discovery of therapeutics that effectively target highly dynamic proteins. Dynamic proteins represent an emerging class of therapeutic targets that can play critical roles in disease progression. Targeting these proteins via a small molecule approach offers a largely untapped means of developing innovative cancer therapies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins